A pathway-based classification of IDH WT GBM identified four metabolically and developmentally distinct subtypes, revealing that mitochondrial GBM exhibits the best prognosis and unique vulnerability to oxidative phosphorylation inhibitors, offering new avenues for precision metabolic therapy (62). The gene discussed is IDH1; the disease is glioblastoma.